BMY 7378 Maxim and gatifloxacin, Bristol-Myers Squibb, Princeton,

BMY 7378 NJ, and penicillin G, Sigma Chemicals, St. Louis, MO was susceptibility testing performed according to the National Committee for Clinical Laboratory Standards guidelines according to the method microdilution with an inoculum of 5104 cfu per well for aerobic and by the agar dilution method with an inoculum of 105 CFU per spot anaerobes. S. pneumoniae ATCC 49 619, ATCC 49 247 H. influenzae, S. aureus ATCC 29213, Escherichia coli ATCC 25922 and Bacteroides fragilis ATCC 25 285 were tested simultaneously with the appropriate plates and environments. The results are shown in Table 1. ABT 492 good results in our study with 325 of 326 isolates of select Nebenh, Both aerobically and anaerobically, sensitive to 4 g of drug / ml for a single Pseudomonas aeruginosa that was resistant to all quinolones tested, has a MIC of ABT 492 16 g / ml in three other isolates, two St strains of A.
xylosoxidans and one strain of Bacteroides uniformis, the MICs of ABT 492 4 g / ml for five other St strains the MIC of ABT was 492 2 g / ABT 492 ml was active against all pneumococci to 0.06 g / ml and was five to seven times more active than levofloxacin, moxifloxacin and gatifloxacin based on INO-1001 the weight. Twenty percent of our pneumococcal sinus isolates were not anf Llig to penicillin and 10% were resistant to clindamycin. ABT 492 showed excellent activity against an isolate that was resistant to other fluoroquinolones. This is consistent with the work of Nilius et al, 30 who studied in S.
pneumoniae resistant to quinolones ABT 492 and found a MIC at which 90% of the isolates tested inhibited of 0.12 g / ml compared to a levofloxacin MIC 90 of 16 g / ml. Smith et al. studied 75 Canadian St strains of ciprofloxacin-resistant S. pneumoniae and reported an MIC 90 of ABT 492 of 0.25 g / ml to MIC90s of gatifloxacin, levofloxacin, moxifloxacin, and 8, 16, and 4 g / ml compared, respectively. Zhanel et al. reported on the activity th comparative ABT 492 in 850 St strains of S. pneumoniae isolates from Canadian patients with infections of the lower respiratory tract in 2002 and found ABT 492 to the pc his strongest means tested against isolates of S. pneumoniae respiratory disease including normal penicillinresistant resistant to macrolides, doxycycline best complete, and quinolone-resistant St strains. In our study, 45% of H.
influenzae and Haemophilus species other isolates were beta-lactamase producers and all were susceptible to all fluoroquinolones tested, with ABT 492 concerning Gt 4 to 10 times more active. The table against Haemophilus species and a continuous K Body of the organism MIC Agent and Agent MIC50 MIC90 MIC50 MIC90 MIC range of amoxicillin Clavulans Acid 0.125 0.125 0.25 0.25 0.25 0.06 Cefuroxime 8 2 8 1 0 , 25 1 clindamycin Peptostreptococcus microphones ABT 492 0.001 0.004 0.004 0.004 0.25 4 0.5 1 moxifloxacin levofloxacin 0125 2 0.25 2 0.25 0.5 0.125 0.5 0.015 0.125 0.015 0.06 0.015 gatifloxacin penicillin G amoxicillin clavulanate cefuroxime 1 2 0.06 0.25 1 0.06 2 0.06 8 0.125 0.25 clindamycin Peptostreptococcus speciesh ABT 492 0.004 0.06 0.008 0.03 0.25 4 2 4 levofloxacin gatifloxacin moxifloxacin 0.25 1 0.125 1 Penicillin G 1 0.5 0.125 1 0.015 2 0.015 0.125 0.5 0.06 0.25 4 amoxicillin clavulanate Enth lt a Haemophilus influenzae and Haemophilus paraphrophilus. Lt B contains the following species: E. coli, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Hafnia alvei, Klebsiella oxytoca, Klebsie